[New domestic phospholipid preparation "Fosfogliv" as an effective treatment for patients with acute viral hepatitis].
Patients with acute viral hepatitis B, A and mixed hepatitis B + C were treated in two independent clinics with phosphogliv--a new hepatoprotective drug based on polyunsaturated phosphatidylcholine and glycyrrhizic acid salt. Phosphogliv removed some symptoms of intoxication (nausea, weakness, jaundice, etc.) quicker than basic therapy. Among biochemical hepatitis markers, serum bilirubin level was most responsive to phosphogliv. Standard therapy decreases bilirubin by 30% on the average for 5 days, phosphogliv reduces bilirubin for one more week to half those values observed in control patients. At that point low aminotransferase activities were seen in phosphogliv treated patients. No side effects were seen. The new hepatoprotector phosphogliv which repairs biomembranes represents drugs of new generation compared to phospholipid drug essential.
Uchaĭkin
V F
VF
Luchshev
V I
VI
Zharov
S N
SN
Kovalev
O B
OB
Ipatova
O M
OM
Tikhonova
E G
EG
Torkhovskaia
T I
TI
Kniazhev
V A
VA
Dunaevskiĭ
O A
OA
Archakov
A I
AI
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D006506:Hepatitis A / Q000188:drug therapy*; D006509:Hepatitis B / Q000150:complications* / Q000188:drug therapy*; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D016896:Treatment Outcome
D000998:Antiviral Agents